# Retatrutide Dosage in the Clinical Trials: Ranges Studied, Half-Life, and Pharmacokinetics > Retatrutide dosage in clinical trials ranged from ~0.5 mg to 12 mg once weekly with escalation; its ~6-day half-life supports weekly dosing [1][4]. Research context only. The weekly subcutaneous doses used across the Phase 1b and Phase 2 program, plus the pharmacokinetics behind them — research context, never a recommendation. ## The short version This page describes the doses retatrutide was given in clinical trials — nothing more. It is not a guide for taking anything. In the studies, retatrutide was given as a once-a-week injection under the skin, starting low and stepping up over several weeks to help the body tolerate it. The trials tested weekly amounts ranging from about half a milligram up to 12 milligrams. Bigger doses tended to produce more weight loss but also more stomach side effects, which is exactly why the studies raised the dose slowly instead of starting high. Because the drug stays in the blood for roughly six days, once-a-week dosing was enough to keep it working. Retatrutide has no approved formulation, and no official standard exists for storing or mixing any non-trial version. Everything below is the studied research range, not a recommended human dose. ## Retatrutide dosage in the clinical trials Across the Phase 2 obesity program, retatrutide was studied at 1, 4, 8, and 12 mg once weekly, reached by stepwise escalation [1]. The Phase 2 type 2 diabetes trial used a 0.5–12 mg once-weekly range, again with dose escalation to manage tolerability [2]. The first-in-human Phase 1b study used ascending weekly regimens of 0.5, 1.5, 3, 3/6, and 3/6/9/12 mg — notation that means the dose was raised at set intervals, for example from 3 to 6 to 9 to 12 mg over successive weeks [4]. The pattern across all three trials is the same: higher weekly doses produced larger weight and glycemic effects, and dose-related gastrointestinal events were the main tolerability limit, which the escalation schedules were built to blunt [1][2]. Escalation is not a formality — it is the mechanism that makes the higher doses usable. Starting low and stepping up gives the gut time to adapt to slowed emptying, so that a dose which would cause significant nausea if given from day one is tolerated when it is reached gradually [1]. In the Phase 2 obesity trial, this is why the 12 mg arm — the one that reached a mean -24.2% body-weight change — was approached over weeks rather than started outright [1]. Every figure here is a trial-administered dose in a monitored setting with clinician oversight and the option to slow or pause escalation. Retatrutide is investigational and unapproved; there is no established human dose, and none is recommended here. ## Retatrutide half-life and pharmacokinetics The pharmacokinetics are what make once-weekly dosing feasible. The Phase 1b trial measured an elimination half-life of approximately six days [4] — the interval over which the blood concentration falls by half — supported by the fatty-diacid acylation that anchors the peptide to circulating albumin. That anchoring is deliberate engineering: the fatty-acid tail binds albumin, the most abundant protein in blood, so the peptide is released slowly rather than filtered out within hours, stretching its action to a weekly interval [4]. That six-day half-life is why every trial used a weekly subcutaneous injection rather than daily dosing [4]. A long half-life also means the drug accumulates toward a steady level over the first several weeks, which is one more reason the trials paired weekly dosing with gradual escalation rather than an immediate high dose. At the highest Phase 1b dose, participants lost 8.96 kg more than placebo over 12 weeks, and daily glucose fell by 2.8 mmol/L at the 3 mg dose [4]. The only route studied is subcutaneous injection — into the fatty layer just beneath the skin — given once weekly [1][2][4]. Retatrutide has been handled solely as a controlled clinical-trial product; no approved formulation, storage, or reconstitution standard exists for any non-trial preparation, and gray-market research-labeled material carries no verified identity, purity, or sterility. The pharmacokinetic figures above describe the trial product, not any material obtained outside a study. ## Dose and effect: what the numbers track together Reading the trials together, dose and effect move in step. In the Phase 2 obesity program, the mean body-weight change deepened as the weekly dose rose across the 1, 4, 8, and 12 mg arms, reaching -24.2% at 12 mg versus -2.1% with placebo [1]. The fatty-liver substudy showed the same gradient in miniature: relative liver-fat reductions of 42.9%, 57.0%, 81.4%, and 82.4% at 1, 4, 8, and 12 mg [5]. In type 2 diabetes, the 12 mg dose drove both the largest HbA1c reduction (2.02 points at 24 weeks) and the largest weight change (16.94% at 36 weeks) [2]. The tolerability side of the ledger tracks dose as well — gastrointestinal events and the modest heart-rate rise were both more common at higher doses [1][2]. This dose-response relationship is exactly why the trials tested a ladder of doses rather than a single amount, and why the highest studied doses are inseparable from the escalation schedules used to reach them. It is a description of the trial data, not a template: retatrutide is investigational, and no dose here is recommended for use outside a study. One more point about interpreting these numbers. A dose-response relationship is part of why the trial evidence is taken seriously — when an effect scales cleanly with dose across independent trials, it is less likely to be noise and more likely to reflect real pharmacology [1][2][5]. But it also means the striking top-dose figures cannot be separated from the higher rate of gastrointestinal effects at those doses, or from the weeks of gradual escalation required to reach them safely under trial supervision [1]. --- An illuminated reading of the retatrutide trial record — Phase 1b pharmacokinetics through the Phase 3 TRIUMPH program, each figure lettered back to its source, and no clinic, prescription, or apothecary behind the page.